research use only

APG-2575 (lisaftoclax) Bcl-2 inhibitor

Cat.No.S9970

APG-2575 (lisaftoclax) is a dual Bcl-2 and Bcl-xl inhibitor with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively.
APG-2575 (lisaftoclax) Bcl-2 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 882.43

Quality Control

Batch: S997001 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.55%
99.55

Chemical Information, Storage & Stability

Molecular Weight 882.43 Formula

C45H48ClN7O8S

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2180923-05-9 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (113.32 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Bcl-2 [1]
2 nM
Bcl-xl [1]
5.9 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06182969 Not yet recruiting
SLE
Ascentage Pharma Group Inc.|Suzhou Yasheng Pharmaceutical Co. Ltd.
December 2023 Phase 1|Phase 2
NCT05495035 Recruiting
Lymphoblastic Leukemia Acute Childhood|Leukemia Lymphoblastic Acute Philadelphia-Positive|Relapsed Leukemia|Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital China
September 1 2022 Phase 1
NCT04496349 Recruiting
T-Prolymphocytic Leukemia
Ascentage Pharma Group Inc.
July 12 2021 Phase 2
NCT04494503 Recruiting
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
August 31 2020 Phase 1|Phase 2
NCT03913949 Active not recruiting
Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma
Ascentage Pharma Group Inc.|Suzhou Yasheng Pharmaceutical Co. Ltd.
June 3 2019 Phase 1
NCT03537482 Recruiting
Hematologic Malignancies
Ascentage Pharma Group Inc.
August 7 2018 Early Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map